Table 3.

Clinical treatment outcomes among patients with drug-resistant tuberculosis treated with a LZD-containing regimen

Characteristic	N = 100
Sputum culture conversion
Overall	95
Time from treatment initiation to sputum culture conversion, days, median [IQR]	92 [58–158]
On LZD, n (%) (n = 79)*	74 (94)
Time from LZD initiation to sputum culture conversion, days, median [IQR]	57 [30–91]
Acquired drug resistance
Prior to starting LZD†	5
On LZD‡	1
Surgical resection§	16
Final outcomes
Cured or completed treatment	79
Lost to follow-up¶	11
Failure	1
Death	9

^*Among patients with positive sputum culture for tuberculosis prior to starting LZD.

^†Capreomycin (n = 3; 63 susceptible at baseline), ethambutol (n = 1; 7 susceptible at baseline), ofloxacin (n = 2; 17 susceptible at baseline), 1 patient with acquired drug resistance to ethambutol and ofloxacin.

^‡Capreomycin (n = 1; 60 susceptible at the time LZD started).

^§Lobectomy (n = 8), segmentectomy (n = 6), pulmonectomy (n = 2)

^¶The median length of treatment prior to loss to follow-up = 380 days; last sputum culture-positive (n = 2).

LZD = linezolid; IQR = interquartile range.